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Strengths and limitations of this study
 ► This will be the first study to analyse the media cov-
erage of the benefits and harms of tests that have 
the potential for overdiagnosis in healthy people.
 ► Media stories will not be restricted by country. The 
results could inform interventions to improve the 
quality of medical reporting in the media.
 ► The study will only consider media coverage of five 
tests.
AbStrACt
Introduction Much testing in medicine is aimed at 
healthy people to facilitate the early detection of health 
conditions. However, there is growing evidence that early 
detection is a double-edged sword that may cause harm 
in the form of overdiagnosis. The media can be seen as a 
major generator of consumer demand for health services. 
Previous research shows that media coverage tends to 
overstate the benefits and downplay the harms of medical 
interventions for the sick, and often fails to cover relevant 
conflicts of interest of those promoting those interventions. 
However, little is known about how the benefits and harms 
of testing the healthy are covered by media. This study will 
examine the media coverage of the benefits and harms of 
testing the healthy, and coverage of potential conflicts of 
interest of those promoting the testing.
Methods and analysis We will examine five tests: 3D 
mammography for the early detection of breast cancer; 
blood liquid biopsy for the early detection of cancer; 
blood biomarker tests for the early detection of dementia; 
artificial intelligence technology for the early detection of 
dementia; and the Apple Watch Series 4 electrocardiogram 
sensor for the early detection of atrial fibrillation. We 
will identify media coverage using Google News and the 
LexisNexis and ProQuest electronic databases. Sets of two 
independent reviewers will conduct story screening and 
coding. We will include English language media stories 
referring to any of the five tests from January 2016 to May 
2019. We will include media stories if they refer to any 
benefits or harms of the test for our conditions of interest. 
Data will be analysed using categorical data analysis and 
multinomial logistic regression.
Ethics and dissemination No ethical approval is required 
for this study. Results will be presented at relevant 
scientific conferences and in peer-reviewed literature.
IntroduCtIon
Much testing in medicine is aimed at appar-
ently healthy people to identify those at an 
increased risk of a disease or disorder.1 These 
‘healthy’ people can subsequently be offered 
more tests, treatment(s) or preventive strat-
egies (eg, a preventive medicine).1 The 
increasing popularity of testing is indicative of 
recent enthusiasm for early detection,2 which 
is part of the promise of ‘precision medicine’. 
That is, early detection is always better, and 
treatment is more effective when it is tailored 
to the individual.3 Apparently healthy or well 
people are increasingly encouraged to proac-
tively monitor, and be vigilant about under-
standing their health, with testing seen as a 
positive step in consumer health empower-
ment. However, there is mounting evidence 
that testing can harm healthy people, and 
the quest for ever-earlier detection of disease 
can lead to unnecessary classification of the 
healthy as sick: overdiagnosis.3–8
Although an exact definition of overdiag-
nosis remains the subject of debate, particu-
larly in the context of non-cancer conditions, 
overdiagnosis can be considered to occur 
when persons are labelled with a technically 
correct diagnosis that does not improve health 
outcomes.9 10 Key drivers of overdiagnosis 
have been identified.11 One is the use of more 
sensitive tests which can detect smaller abnor-
malities, many of which are benign.11 There 
is growing evidence demonstrating the pres-
ence of overdiagnosis, often arising through 
testing healthy people, across different areas 
of medicine. Examples include screening for 
cancer (eg, breast, prostate, thyroid), cardio-
vascular disease and dementia.7 8 12–16 Inap-
propriate screening in this context is likely to 
lead to higher healthcare spending and worse 
outcomes (eg, psychological effects and 
unnecessary and harmful treatments).17–21
Sustained promotion to the public, 
patients and clinicians of the importance 
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of early detection and testing, including via the media, 
is considered another driver of overdiagnosis.11 Uncrit-
ical coverage of new tests, without consideration of their 
potential downsides, contributes to the general lack of 
knowledge about the potential harms of getting tested 
when healthy. In fact, research has shown that only a small 
proportion of people are knowledgeable about overdiag-
nosis.22 23 This includes individuals offered tests where the 
potential for overdiagnosis is high.22 23 As such, patients 
(and clinicians) overestimate the benefits of testing, while 
underestimating the harms.24 25
There is also concern about how changing media envi-
ronments, such as the rising influence of social media, 
can lead to ‘junk-food news’.26 Indeed, previous studies 
on the media have identified evidence of exaggera-
tion,27 28 inaccurate media coverage of published scien-
tific papers,29 30 overstating of benefits of treatments, 
downplaying of harms27 29 and failure to report important 
conflicts of interest of the experts cited in the story.27 
Concern has also been expressed about the financial 
closeness between journalists and industry. For example, 
pharmaceutical industry funding of journalism practice, 
awards and education, has been documented.31 32 Further, 
there appears to be a lack of independent medical 
research commentators in the media. Only one in six 
media reports of research published in high-impact 
medical journals included comments from people who 
were independent of the study investigators.33 Moreover, 
one in three of the independent commenters had finan-
cial conflicts of interest, most of which were not disclosed 
in the media stories.33
Poor media coverage of medicine is a significant issue; it 
can influence how the public perceives the risk of health 
services and how patients make treatment decisions.29 31 
For example, media coverage about the celebrity Kylie 
Minogue’s self-referral mammogram bookings led to a 
20-fold increase in media coverage about breast cancer 
and a 40% increase in mammogram bookings during the 
2-week peak after the interview.34 Six weeks later, media 
coverage was still up by 30%.34
Media coverage of overtreatment has been examined 
in one study35 which examined the framing of medical 
overtreatment in United States (US) newspapers from 
January 2007 to December 2010. The study found that the 
media focused on the harms of overtreatment relating to 
cancer, but the overall media coverage may have implied 
that overtreatment was not seen as an issue across other 
health conditions.
To date, however, no studies have examined media 
coverage of new tests with significant potential for overdi-
agnosis. Furthermore, there has been little formal, 
rigorous evaluation of the media's coverage of testing 
healthy people. An evaluation may give us an insight 
into how the media can contribute to overdiagnosis, and 
inform potential strategies to enhance media coverage 
of medical testing. In this study, we aim to examine the 
media coverage of the benefits and harms of testing the 
healthy, and the potential conflicts of interest of those 
promoting the testing, by examining the coverage of five 
tests.
MEthodS And AnAlySIS
overview
We will conduct a large descriptive cross-sectional study of 
global English-language media coverage of five tests from 
January 2016 to May 2019.
tests and conditions of interest
This study will focus on five tests:
1. 3D mammography for the early detection of breast 
cancer
2. Blood liquid biopsy tests for the early detection of can-
cer(s)
3. Blood biomarker tests for the early detection of de-
mentia
4. Artificial intelligence (AI) technology for the early de-
tection of dementia
5. Apple Watch Series 4 ECG sensor for the early detec-
tion of atrial fibrillation (AF)
We identified these tests based on the following criteria
1. Evidence-based concerns about overdiagnosis
2. Evidence of Food and Drug Administration (FDA) ap-
proval for certain classes of each test
3. Concern that the results of these tests may not lead to 
improved health outcomes for some individuals; either 
due to the unavailability of effective treatment options 
(eg, dementia) or treatments that may cause more 
harm than benefit (eg, early mammography)
4. Identifiable groups or companies with a financial in-
terest in promoting these tests, or maximising the mar-
kets for downstream treatments
5. Notable media coverage
One reviewer (MO) used Google News to track media 
coverage of tests for the healthy between April 2018 and 
October 2018. Results were recorded in a Microsoft Excel 
file. Based on these results, the same reviewer designed a 
series of Google Alerts (running between April 2018 and 
December 2018) with specific keywords related to testing. 
The Google Alert results were screened to identify media 
coverage on tests for healthy people which met the first 
four criteria mentioned above. Consideration was given 
to conducting a descriptive study of a random sample of 
recent media coverage for all tests. However, we felt that 
tracking a specific number of tests over time would give 
us a more comprehensive picture of how the benefits and 
harms of testing were reported in the media over time. 
Five tests that were receiving notable media coverage 
were included. Below we provide details of the five iden-
tified tests.
3D mammography for the early detection of breast cancer
3D mammography or digital breast tomosynthesis is 
an advancement on traditional mammography. Many 
companies have received FDA approval for 3D mammog-
raphy,36–38 partially based on an emerging body of evidence 
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on its detection capability relative to 2D mammography 
screening.39 In March 2019, the FDA announced new 
policies to change current mammography standards in 
the US. The proposed changes aim to increase the use of 
3D mammography screening.
There is a high level of uncertainty surrounding the 
benefits of 3D mammography. For example, a system-
atic review and meta-analysis40 found that 3D mammog-
raphy improves cancer detection rate and reduces recall 
for assessment compared with traditional mammog-
raphy. However, these improvements varied by setting; 
compared with retrospective studies in the US where 
annual screening was encouraged, there were greater 
improvements observed in prospective studies embedded 
in the European biennial screening programme.
There is a large amount of research on the benefits 
and harms of mammography, particularly compared 
with the other four tests we selected. Overdiagnosis is 
a significant harm of screening mammography, and 
notwithstanding uncertainty in the data, there are esti-
mates of its frequency ranging between 10% and 50% 
of screen-detected cancers.12 41 Overdiagnosis of breast 
cancer can lead to unnecessary surgery, radiotherapy and 
endocrine therapies, as these are standard treatments for 
women with screen-detected cancers.12 20 41 These treat-
ments cause harm through physical and psychological 
effects that can impact on quality of life.18 Overall, little is 
known about whether the improved cancer detection rate 
estimated for 3D mammography screening—compared 
with 2D mammography screening—will have additional 
benefit (ie, whether it will further reduce breast cancer 
mortality and/or increase quality of life) or whether it 
will lead to harms (eg, overdiagnosis), or a combination 
of both.
Liquid biopsy for the early detection of cancer
A liquid biopsy is a blood test using genomic profiling 
to detect mutations or cancer cells (circulating tumour 
DNA cells).42 The FDA approved the first liquid biopsy 
in 2016.43 This class of liquid biopsy was designed for 
clinicians to monitor cancer status and patient response 
to treatment. The FDA has since (April 2018) approved 
another liquid biopsy test by a molecular information 
company called Foundation Medicine.44
While liquid biopsy was initially designed for monitoring 
patients with cancer, there seems to be increasing interest 
in its use for the early detection of cancer, and that the 
test may eventually be used for routinely screening people 
and detecting cancers before they cause symptoms.45 In 
fact, there are ongoing studies assessing whether the test 
can detect tumours in seemingly cancer-free individuals.45 
There is a lot of uncertainty surrounding the effectiveness 
of liquid biopsy for both early detection, and improve-
ment of cancer treatment.46
There are also concerns that the detection of circu-
lating tumour DNA cells in asymptomatic populations 
could lead to overdiagnosis.47 The concerns are linked 
to findings that circulating tumour DNA cells and 
cancer-related mutations have been detected in healthy 
individuals who never go on to develop a cancer.48 49 It 
has also been mentioned that the cancer-related proteins 
used by liquid biopsy can reflect tissue damage common 
in inflammatory conditions like arthritis, in the absence 
of cancer.45
Blood biomarker tests for the early detection of dementia
There is enormous interest in identifying a cheap and 
simple test to detect dementia in the early stages, with 
the hope this will improve the treatment of dementia. In 
recent years, there has been particular interest in blood 
tests to detect abnormal levels of two proteins: amyloid 
beta and tau.50 51 Both are considered biomarkers of 
dementia.50 The FDA granted approval to a genetic 
company called ‘23andMe’ in 2017 to offer direct to 
consumer tests for the early detection of dementia.52 
The decision has generated controversy with commenta-
tors concerned about what they see as a lack of robust 
evidence to support the testing in the early detection of 
dementia, concerns about overdiagnosis53 and the impli-
cations of testing a condition that has not yet been shown 
to be amenable to intervention.51 53 54
In January 2019, the Cochrane Dementia and Cognitive 
Improvement Group published a commentary expressing 
their concerns about the increasing use of biomarker 
tests in dementia.53 In their commentary, they referred to 
research demonstrating that up to 60% of healthy people 
over 80 years could be labelled as having dementia under 
new disease definitions, even though these people may 
never develop clinical symptoms.55 In the same commen-
tary, the authors stated that reducing dementia to positive 
amyloid biomarkers is ‘an open invitation to overdiag-
nosis’.53 Further to this, authors refer to the data docu-
menting the psychological, social and legal harms of over 
diagnosing or overpredicting dementia.56 Finally, they 
expressed concerns about the lack of data validating the 
proposed biomarkers for dementia.57
Artificial Intelligence (AI) technology for the early detection of 
dementia
Similarly to blood tests, there is a keen interest in using 
artificial intelligence (AI) technology to improve the early 
detection of dementia. AI refers to the use of machine 
algorithms (eg, computer programmes) to model intel-
ligent behaviour with minimal human intervention.58 
The FDA has now approved one type of AI technology to 
monitor brain structures in different neurological condi-
tions, including dementia.59 Since February 2018, the 
FDA have also relaxed regulatory policies on drugs for 
dementia so they could approve the delivery of disease 
treatments to people displaying certain biological signals 
years before the disease shows outward signs. AI tech-
nology has been proposed as a key step in detecting these 
subtle biological signals of dementia (eg, small changes 
in brain size, metabolic changes, memory recognition, 
voice recognition, etc.). Researchers have expressed 
concerns about the lack of robust clinical research in this 
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area, and the potential of AI to lead to false positives, and 
overdiagnosis.60
Apple Watch Series 4 electrocardiogram (ECG) sensor for the early 
detection of atrial fibrilliation (AF)
The Apple Watch Series 4 was released in 2018. It features 
an electrocardiogram (ECG) sensor that has received 
FDA medical device approval.61 The primary rationale 
for this new sensor is to facilitate the early detection of 
atrial fibrillation (AF). AF is the most common heart 
arrhythmia (irregular heartbeat), and can be associated 
with an increased risk of early mortality, heart failure 
and stroke.62–64 Because of this, a diagnosis of AF can 
often lead to drug therapy and in some cases, surgery.63 
The Apple Watch ECG sensor records electrical impulse 
patterns of a person’s heart to predict AF. The sensor 
will inform the user of the presence of AF and advise on 
the need for medical consultation. Many concerns have 
been expressed about testing the healthy for AF, and it 
has been suggested that overdiagnosis is ‘only a matter 
of time’ with the Apple Watch.65–67 There is a concern 
regarding the poor specificity of testing methods for AF.66 
Furthermore, AF has a low prevalence68 and screening 
the healthy could potentially lead to harms in the form of 
false positives, overdiagnosis and overtreatment.67 In fact, 
some researchers state that the Apple Watch specifically 
could lead to a misdiagnosis of AF in ~1 million people 
for every 10 million screened.67 This may lead to harms 
from overtesting, bleeding from unnecessary anticoag-
ulation and anxiety due to having a cardiac diagnosis.67 
There also seems to be a lack of knowledge around the 
natural history of AF. For example, there is uncertainty 
surrounding the outcome of untreated stroke risks, so the 
net benefit of treating AF with anticoagulants is unclear. 
Finally, while screening for AF leads to increased detec-
tion, office visits and prescriptions for anticoagulants,69 
there is still uncertainty around its effects on health 
outcomes.
Inclusion and exclusion criteria
We will include media stories referring to any of our five 
target tests for the corresponding conditions of interest. 
Media stories will be included if they refer to any benefits 
(eg, early detection of the condition, early treatment of 
the condition, prevention of the condition, saves lives) or 
harms of the test (eg, overdiagnosis, inappropriate diag-
nostic testing, misdiagnosis, false alarms, false positives, 
false negatives, unnecessary and/or harmful treatment, 
psychological distress, health anxiety, costs). We will 
exclude media stories that only focus on tests for symp-
tomatic people or people who already have the condi-
tion of interest (eg, mammography for monitoring the 
progression of breast cancer), media stories about patent 
approval or business issues only, press releases, confer-
ence proceedings, trade journal reports and scholarly 
journal articles. We will first pilot our screening process. 
Depending on the results of the pilot, we may add 
additional criteria, or provide more detail on the current 
inclusion and exclusion criteria.
Search strategy
We will identify all relevant English-language media 
stories by searching the LexisNexis and ProQuest elec-
tronic databases, using explicit keywords, from January 
2016 to May 2019. In line with a previous study on media 
coverage of medicine,70 we will supplement this database 
search with a Google News search, reviewing the first 20 
pages of each Google search result. Different keywords 
will be required for each of the five tests; therefore, five 
searches (one specific to each test) will be performed. A 
librarian/information specialist with expertise in system-
atic review search design will assist with the search strategy. 
We will not restrict articles by country. Our searches will 
cover all of the following media coverage: newspapers, 
major world publications, blogs, magazines, broadcast 
and podcast transcripts, wire feeds/services and webnews. 
These are named categories within the LexisNexis and 
Proquest databases.
Screening process
Sets of two independent reviewers will be involved in 
performing the screening of media stories for each test. 
We will exclude exact duplicates (same title, same outlet 
and same date) before starting the screening and will 
keep track of the number of duplicates. Reviewers will 
independently assess the eligibility of media reports for 
potential inclusion according to the predefined selection 
criteria. Any disagreements in judgement will be resolved 
by discussion to reach consensus or by consultation with 
a third reviewer. Syndicated studies will be included but 
will only be coded once. For example, if there are 10 
media stories about the Apple Watch where the same 
or extremely similar story has been run across multiple 
media outlets, we will code this story once, but include 
the number 10 as the number of media reports about the 
Apple Watch.
data extraction and coding
We will use a structured template (see table 1) to extract 
and code the relevant data in Research Electronic Data 
Capture hosted at The University of Sydney.71 The data 
extraction tool will be adapted from tools used in similar 
studies27 70 72 and an iterative design process will be used 
to refine the tool for the purpose of our study. Sets of 
two independent reviewers will extract data and code 
the media stories; two independent reviewers for each 
test. Any disagreements in extraction or coding will be 
resolved by discussion to reach consensus or by consul-
tation with a third reviewer . The percentage of disagree-
ments on each coding variable requiring resolution 
through use of a third reviewer will be recorded. Before 
formal data extraction and coding, the sets of indepen-
dent reviewers will apply the data extraction tool to code 
20 media stories; four for each test. Disagreements in 
data extraction and coding will be resolved by discussion 
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Table 1 Draft coding tool
Media story description
Name of media source eg, New York Times
Country of media source
Word count
Release date
Author name
Type of media eg, 1=newspaper, 2=magazine, 3=radio, 
4=TV, 4-blog/opinion piece, 4-wire news, 
5=unclear/not stated
Test mentioned In the headline 1=Yes, 0=No
In the body 1=Yes, 0=No
Mention of the health condition that the 
test is used for?
Yes/No 1=Yes (record condition)
0=No
Context about the screening test (benefits and harms)
How benefit was described
Any benefit mentioned or implied? Yes/No 1=Yes, 0=No
Any benefit quantified? Yes/No 1=Yes (record how quantified)
0=No
Was anecdote or other real-life example 
of benefit given?
Yes/No 1=Yes, 0=No
Anecdote 1=Yes, 0=No
Celebrity 1=Yes, 0=No
Benefits referred to as revolutionary, 
life-saving, breakthrough, leading to 
improved treatment
How harm was described
Any harm mentioned or implied? 1=Yes, 0=No
Any harm quantified? 1=Yes (record how quantified)
0=No
Was anecdote or other real-life example 
of harm given?
Yes/No 1=Yes, 0=No
Anecdote 1=Yes, 0=No
Celebrity 1=Yes, 0=No
Any specific harms of screening 
mentioned? (eg, overdiagnosis, potential 
overtreatment)
1=Yes (record specific harm)
0=No
Evidence of conflicts of interest
Any specific scientific study quoted or 
mentioned about the screening test?
Yes/No 1=Yes, 0=No
Does the scientific study disclose 
any financial ties of the authors to the 
manufacturers of the screening test 
discussed in story?
1=Yes, 0=No
If yes, state verbatim
Did the media story include information 
about financial ties of the authors to the 
manufacturer of the screening test? (if 
relevant)
1=Yes, 0=No
Does the scientific study mention receipt 
of study funding from the manufacturers 
of the screening test discussed in story?
1=Yes, 0=No
Did the media story include information 
about receipt of study funding from the 
manufacturers of the relevant screening 
test? (if relevant)
1=Yes, 0=No
Continued
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Other sources quoted or mentioned 
about the screening test
Yes/No 1=Yes, 0=No
Physician/provider? 1=Yes, 0=No
Patient quoted? 1=Yes, 0=No
Other source? 1=Yes, 0=No
Overall impressions/tone
Media story leaves you with sense that 
the screening test is
1=Beneficial overall
2=Harmful overall
3=Neutral (balanced information given 
about benefits and harms)
4=Unclear
Overall tone about going for the 
screening test
1=Overall positive (worth getting)
2=Overall negative (avoid it)
3=Neutral (balanced information about 
benefits and harms)
Paste in anything else unusual, 
interesting or any especially juicy 
quotes (including source) (eg, screening 
tests being lifesaving, a breakthrough, 
revolutionary)
Leave a comment or paste here anything 
interesting (even quotes)
This is a draft coding tool. The tool may be modified once the reviewers pilot test it with a sample of included media stories.
Table 1 Continued
and subsequent revisions to the data extraction tool. We 
plan to extract information about the media story (eg, 
type of media, test mentioned, country of origin), bene-
fits mentioned, harms mentioned, disclosure of conflicts 
of interest and the overall tone of the story (positive or 
negative)).
data analysis
Descriptive statistics (means, SD, counts and percentages) 
will be used to summarise the extracted data (eg, number 
of stories, number of countries, number reporting bene-
fits and harms, etc.). Analysis will be performed separately 
for each test. Categorical data analysis will be used to inves-
tigate potential associations between overall impression 
of the media reports and explanatory variables including 
conflicts of interest, time and type of media. We plan to 
use multinomial logistic regression where the dependent 
variable is overall impression and a neutral impression 
is the reference category. We will report odds ratios and 
95% CIs for negative impressions and positive impressions 
associated with the independent explanatory variables (as 
referred to above). Analysis will be conducted separately 
for each test. We will use χ2 tests to compare the distribu-
tion of categories of overall impressions across the five 
tests. We will also outline at least one example of a media 
story for each test in the Results section.
Ethical considerations
No ethical approval is required for this study.
Patient or public involvement
Patients and members of the public were not involved in 
the design of this study.
dissemination
The results of this study will be published and presented at 
relevant medical conferences. We anticipate the results of 
this study will inform the development of an intervention 
to improve the quality of medical reporting in the media.
dISCuSSIon
This study will examine media coverage reporting the 
benefits and harms of five medical tests that are contro-
versially being promoted to the healthy. While other 
drivers, including research and professional prominence 
given to early detection,2 are important, sustained media 
coverage is likely a powerful source of influence of public 
attitudes towards new tests. The results will provide valu-
able information about the quality of media reporting on 
tests targeting the healthy and may help inform interven-
tions to improve the quality of medical reporting.
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